000			03787nam a22003375i 4500
001			75980
003			ES-MaUEC
005			20230207040204.0
007			cr nn 008mamaa
008			130722s2013 xxu| s |||| 0|eng d
020			_a9781461472919
040			_aES-MaUEC
050		4	_aQR201.A37 _bH86 2013 EB
245	0	0	_aHuman Immunodeficiency Virus Reverse Transcriptase : _bA Bench-to-Bedside Success _cedited by Stuart LeGrice, Matthias Gotte
260			_aNew York _bSpringer International Publishing _c2013
300			_a1 recurso en línea (X, 361 p.) 72 il., 47 il. col.
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
520			_aThe Reverse Transcriptase (RT) of Human Immunodeficiency Virus Type 1 (HIV-1) arguably ranks amongst one of the most extensively studied retroviral enzymes. Heterologous expression and purification of HIV-1 RT in the early eighties, approval of the first nucleoside analogue RT inhibitor (NRTI) in 1987, discovery of resistance to RT inhibitors, approval of the first non-nucleoside analogue RT inhibitor (NNRTI) in 1996 and the various crystal structures of RT with and without bound substrate(s) and/or inhibitors represent only a few of the important milestones that describe the a bench-to-bedside success in the continuing effort to combat HIV-1 infection and its consequences. Nucleoside and nonnucleoside RT inhibitors remain important components in frequently used drug regimens to treat the infection. RT inhibitors also play important roles in recently validated strategies to prevent transmission of the virus. The relevance of HIV-1 RT as a drug target has simultaneously triggered interest in basic research studies aimed at providing a more detailed understanding of interactions between proteins, nucleic acids, and small molecule ligands in general terms. In light of the ever-growing knowledge on structure and function of HIV-1 RT, this enzyme serves as a valuable “model systemâ€{u0A6E} efforts to develop novel experimental tools and to explain biochemical processes. This monograph is designed to provide an overview of important aspects in past and current HIV-1 RT research, with focus on mechanistic aspects and translation of knowledge into drug discovery and development. The first section includes chapters with emphasis placed on the coordination of the RT-associated DNA polymerase and ribonuclease H (RNase H) activities. The second covers mechanisms of action and future perspectives associated with NRTIs and NNRTIs, while the third section includes chapters focusing on novel strategies to target the RT enzyme. Chapters of the final part are intended to discuss mechanisms involved in HIV variability and the development of drug resistance. We hope that these contributions will stimulate interest, and encourage research aimed at the development of novel RT inhibitors. The lack of bona fide RNase H inhibitors with potent antiviral activity provides an example for challenges and opportunities in the field.
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGERrevisado
650		7	_aInfecciones por VIH _2embne _9154434
700	1		_aLeGrice, Stuart _eeditor _0Local _984757
700	1		_aGotte, Matthias _eeditor literario _984758 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4614-7291-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9781461472919
907			_a.b12815986 _b10-10-17 _c01-10-14
998			_am _a_alco _a_vill _b22-03-17 _cm _dz _eu _feng _gxxu _h0
945			_aQR201.A37 H86 2013 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11545367 _z06-04-17
999			_c75980 _d75980 _x1